<DOC>
	<DOC>NCT02466516</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of GS-4997 alone or in combination with Simtuzumab (SIM) in adults with Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3. Participants will be randomized in a 2:2:1:1:1 ratio to 1 of 5 study treatment arms.</brief_summary>
	<brief_title>Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Key Males and nonpregnant, nonlactating females Evidence of NASH with fibrosis on biopsy Key Cirrhosis of the liver (e.g. Brunt/Kleiner score of F4) Other causes of liver disease including viral hepatitis and alcoholic liver disease Any history of decompensated liver disease, including ascites, hepatic encephalopathy or variceal bleeding History of liver transplantation Alcohol consumption greater than 21 oz/week for males or 14 oz/week for females (1 oz/30 mL of alcohol is present in 1 12 oz/360 mL beer, 1 4 oz/120 mL glass of wine, and a 1 oz/30 mL measure of 40% proof alcohol) Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GS-4997</keyword>
	<keyword>Non-alcoholic fatty liver disease (NAFLD)</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Simtuzumab</keyword>
</DOC>